Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000902664-25-004480
Filing Date
2025-10-21
Accepted
2025-10-21 09:04:14
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 12025
  Complete submission text file 0000902664-25-004480.txt   14049
Mailing Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850
Business Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850 (734) 332-7800
Theriva Biologics, Inc. (Subject) CIK: 0000894158 (see all company filings)

EIN.: 133808303 | State of Incorp.: NV | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-50777 | Film No.: 251405482
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 1 ROCKEFELLER PLAZA, SUITE 1205 NEW YORK NY 10020
Business Address 1 ROCKEFELLER PLAZA, SUITE 1205 NEW YORK NY 10020 212-608-3300
Empery Asset Management, LP (Filed by) CIK: 0001469336 (see all company filings)

EIN.: 262107121 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A